One in nine Americans age 65 and older has Alzheimer’s disease (AD), a devastating illness that gradually erodes memory and cognitive function, affecting patients and their families long before the disease reaches its final stages.¹ As the population ages, the burden will continue to grow. By 2030, 20% of the U.S. population is expected to be age 65 or older, increasing the number of people at risk for developing Alzheimer’s disease.¹
There is still no cure for this progressive and fatal form of dementia. While seven therapies have received approval from the Food and Drug Administration (FDA) and more than 180 clinical trials are evaluating potential treatments, developing effective therapies remains a complex challenge.¹ ²
Advancing Alzheimer’s research requires a deeper understanding of how the disease is diagnosed, monitored and treated across real-world care settings. taXonomy Pathways brings together claims, lab results and electronic health records (EHR) into research-ready datasets that allow investigators to study the Alzheimer’s patient journey and generate evidence to support new treatment development.
The Alzheimer’s Association reported that clinical trial sites for memory impairment drugs do not cohesively align with areas that have larger populations of individuals 60 years of age and older, causing strain on sites in areas of higher density senior populations and leaving other individuals having to travel 50 miles to get to a clinical trial site. This has led to lower performance and delayed timelines.3 Additionally, Alzheimer’s disease disproportionately affects minorities, with 19% of Black/African American and 14% of Hispanic/Latino adults age 65 and older having AD, compared to 10% of White/Caucasian seniors.1
HealthVerity RWD allows researchers to analyze the demographic composition of patient populations across the healthcare system. By combining medical claims, pharmacy data and social determinants of health signals, investigators can identify providers who treat patient populations most affected by Alzheimer’s disease.
This approach helps research teams select clinical trial sites that better reflect real-world disease burden, improving recruitment and supporting more representative study populations.
In order for new Alzheimer's drugs to be accepted by doctors, payers, regulators and, most importantly, patients, pharmaceutical companies need to create a robust body of evidence that demonstrates product safety and effectiveness in the real world. This presents unique challenges, because traditional sources of real-world data (RWD), such as claims or electronic medical records (EMRs) alone, do not capture key measures of AD progression.
With the nation’s largest healthcare and consumer data ecosystem, representing over 4 million diagnosed AD patients, HealthVerity offers the most novel and diverse data sources, including:
All of this data is fully interoperable, privacy-protected and delivered directly to your environment of choice in a normalized common data model for you to apply fit-for-purpose analytics.
Nearly 14 million people in the U.S. are expected to live with Alzheimer’s disease by 2060.1 Advancing research requires more than claims data alone. With taXonomy Pathways, HealthVerity brings together closed claims, lab results and electronic health records into research-ready datasets that allow investigators to study diagnosis, testing patterns and treatment use across the Alzheimer’s patient journey.
Through the HealthVerity IPGE approach, we bring together identity resolution, privacy protections and governance controls that support accurate patient matching across disparate datasets while respecting data rights and usage permissions. Frameworks such as taXonomy Pathways build on this foundation, organizing integrated claims, lab and electronic health record data into research-ready patient journeys.